Literature DB >> 28350269

Review of a single surgeon's stapedotomy cases performed with a nickel titanium prosthesis over a 14-year period.

Natalie Justicz1, Kaitlyn F Strickland1, Kevin K Motamedi1, Douglas E Mattox1.   

Abstract

CONCLUSION: Stapes surgery with a nickel titanium prosthesis is a safe and well-tolerated procedure that leads to a significant improvement in hearing outcomes.
OBJECTIVE: To identify the efficacy and safety of stapedotomy procedures performed with a nickel titanium prosthesis for patients with otosclerosis.
METHODS: A review of 431 unique stapedotomies performed over 14 years by a single surgeon at an academic tertiary care center yielded 312 cases with nickel titanium prosthesis that met inclusion criteria of otosclerosis diagnosis, initial surgery in operative ear, and presence of pre-operative and post-operative audiograms. Pure-tone averages (PTA) at baseline and 8 weeks after surgery were calculated over four frequencies; 0.5, 1, 2, and 4 kHz. Average air-bone gaps (ABG) were calculated from pre-operative and post-operative audiograms.
RESULTS: Average pre-operative baseline PTA was 56.7 dB in the affected ear. Post-operative PTA was 30.1 dB, a 26.6 dB improvement. Initial average ABG was 29.7 dB, while post-operative ABG averaged 5.4 dB, a 24.2 dB improvement. Surgical success (closure of ABG within 10 dB) was achieved in 263 (84%) patients. Rate of surgical success was not correlated with age, gender, race, or affected ear. Complications included recurrent conductive hearing loss (14), progressive SNHL (4), and post-operative BPPV (3).

Entities:  

Keywords:  Otosclerosis; SNHL; hearing; middle ear; stapedotomy

Mesh:

Substances:

Year:  2017        PMID: 28350269     DOI: 10.1080/00016489.2016.1258732

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Endoscopic stapedotomy: safety and audiological results in 150 patients.

Authors:  Luca Bianconi; Luca Gazzini; Elisa Laura; Stefano De Rossi; Alessandro Conti; Daniele Marchioni
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-17       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.